The short answer
SURMOUNT-OSA tested tirzepatide in adults with moderate-to-severe obstructive sleep apnoea and obesity across two 52-week studies. In participants not using positive airway pressure, mean apnoea-hypopnoea index fell 27.4 events per hour against 4.8 on placebo, a 55.0% reduction against 5.0%.
Key facts
- Trial
- SURMOUNT-OSA, two 52-week studies
- Publication
- NEJM, October 2024 (PMID 38912654)
- Study 1 population
- Not using PAP therapy
- Study 1 AHI reduction
- 27.4 events/hour vs 4.8 placebo
- Study 1 percentage
- 55.0% vs 5.0%
- Study 2 (on PAP)
- 30.4 events/hour vs 6.0 placebo
- Weight reduction
- 18.1% vs 1.3% (Study 1)
- Estimand
- Efficacy estimand
Why sleep apnoea is a coherent target
Obstructive sleep apnoea occurs when the upper airway collapses repeatedly during sleep. Excess soft tissue around the airway is one contributor, and body weight is strongly associated with severity. A compound producing 18% weight reduction therefore has a plausible mechanical route to reducing apnoea severity. This is a fairly direct consequence rather than an unexpected pleiotropic effect.
What AHI measures
The apnoea-hypopnoea index counts breathing interruptions per hour of sleep. Roughly, 5 to 15 is mild, 15 to 30 moderate and above 30 severe. Because it is an event rate rather than a symptom score, a change of 27.4 events per hour is a large absolute movement, enough to shift a participant across severity categories rather than within one.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The two studies and why they were split
Study 1 enrolled participants not using positive airway pressure therapy; Study 2 enrolled those using PAP and continuing it. Splitting them matters because PAP is an effective existing treatment, and a drug's contribution on top of PAP is a different question from its effect in people not using it. Study 2 reported a mean AHI reduction of 30.4 events per hour against 6.0 on placebo.
What else moved
Beyond AHI and body weight, the published results reported reductions in hypoxic burden, high-sensitivity C-reactive protein and systolic blood pressure, alongside improvement in sleep-related patient-reported outcomes. The last of those matters most clinically: an event-rate improvement that patients do not notice would be a weaker result than one they report feeling.
The estimand, again
The reported figures are for the efficacy estimand (participants adhering to treatment), which the release states explicitly. As with CagriSema's 22.7% and SURMOUNT-1's 22.5%, quoting the figure without naming the estimand overstates what a treatment-policy analysis would show. The consistency of this pattern across the field is why it should be checked every time.
Why this approval mattered
It moved an incretin into a non-metabolic indication with an objective, instrument-measured endpoint. AHI is recorded by polysomnography, not reported by the participant, which makes it harder to attribute to expectation effects than a symptom questionnaire. That strengthens the broader case that weight reduction at this magnitude produces measurable downstream change.
Quick reference
| Endpoint (52 wks) | Tirzepatide | Placebo |
|---|---|---|
| AHI reduction, Study 1 | 27.4 events/hr | 4.8 events/hr |
| AHI percentage, Study 1 | 55.0% | 5.0% |
| AHI reduction, Study 2 | 30.4 events/hr | 6.0 events/hr |
| Body weight, Study 1 | −18.1% | −1.3% |
Frequently asked questions
Does tirzepatide cure sleep apnoea?
The trials report large reductions in apnoea-hypopnoea index, not elimination. Mean AHI fell substantially but participants were not reported as free of the condition.
Is the benefit just from weight loss?
Weight reduction is the most plausible route, given the mechanical relationship between soft tissue around the airway and apnoea severity. The trials were not designed to separate the two.
Why were there two studies?
One enrolled participants using positive airway pressure therapy and one did not. A drug's effect on top of an existing effective treatment is a different question from its effect alone.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedMalhotra A et al., Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. NEJM 2024 (PMID 38912654)pubmed.ncbi.nlm.nih.gov
- PubMedMalhotra A et al., SURMOUNT-OSA rationale and design. Contemp Clin Trials 2024 (PMID 38547961)pubmed.ncbi.nlm.nih.gov
- RefTirzepatide reduced sleep apnoea severity. Eli Lillyinvestor.lilly.com
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Why GLP-1 Receptors Turn Up in Reward ResearchGLP-1 receptors are expressed in mesolimbic reward circuitry, not only in appetite regions. That expression is the mechanistic basis for the craving findings.
- Why GLP-1 Drugs Matter Before AnaesthesiaDelayed gastric emptying means a fasted patient on a GLP-1 may still have stomach contents. Ultrasound studies, and why this is a mechanism-linked risk.
- GLP-1 Gastrointestinal Safety SignalsGastroparesis, pancreatitis and bowel obstruction have all been raised as GLP-1 signals. What the comparative cohort data shows, and how the compounds differ.
- How to Read a Pharmacovigilance SignalA reporting odds ratio of 19 does not mean a nineteen-fold risk. What FAERS disproportionality measures actually mean, and why they are so often misreported.
- Danuglipron: The Oral GLP-1 Pfizer StoppedPfizer halted danuglipron in April 2025 after one asymptomatic liver injury case. Why a single event ended a programme that had met its objectives.